These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26761707)

  • 21. A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model.
    Fullen DJ; Murray B; Mori J; Catchpole A; Borley DW; Murray EJ; Balaratnam G; Gilbert A; Mann A; Hughes F; Lambkin-Williams R
    PLoS One; 2016; 11(12):e0166113. PubMed ID: 27936016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
    McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.
    Fiore AE; Shay DK; Broder K; Iskander JK; Uyeki TM; Mootrey G; Bresee JS; Cox NJ;
    MMWR Recomm Rep; 2009 Jul; 58(RR-8):1-52. PubMed ID: 19644442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
    Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
    Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a candidate live attenuated influenza vaccine prepared in Changchun BCHT (China) for safety and efficacy in ferrets.
    Shen Z; Bowen RA; Ge P; Yu J; Shen Y; Kong W; Jiang C; Wu J; Zhu C; Xu Y; Wei W; Rudenko L; Kiseleva I; Xu F
    Vaccine; 2016 Nov; 34(48):5953-5958. PubMed ID: 27997342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.
    Andrews N; McMenamin J; Durnall H; Ellis J; Lackenby A; Robertson C; von Wissmann B; Cottrell S; Smyth B; Moore C; Gunson R; Zambon M; Fleming D; Pebody R
    Euro Surveill; 2014 Jul; 19(27):5-13. PubMed ID: 25033051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection.
    Rennie P; Bowtell P; Hull D; Charbonneau D; Lambkin-Williams R; Oxford J
    Respir Res; 2007 May; 8(1):38. PubMed ID: 17509128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.
    Smith G; Liu Y; Flyer D; Massare MJ; Zhou B; Patel N; Ellingsworth L; Lewis M; Cummings JF; Glenn G
    Vaccine; 2017 Sep; 35(40):5366-5372. PubMed ID: 28844407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and Control of Seasonal Influenza with Vaccines.
    Grohskopf LA; Sokolow LZ; Broder KR; Olsen SJ; Karron RA; Jernigan DB; Bresee JS
    MMWR Recomm Rep; 2016 Aug; 65(5):1-54. PubMed ID: 27560619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.
    DeDiego ML; Anderson CS; Yang H; Holden-Wiltse J; Fitzgerald T; Treanor JJ; Topham DJ
    Immunology; 2016 Jun; 148(2):160-73. PubMed ID: 26854888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
    Lambkin-Williams R; Gelder C; Broughton R; Mallett CP; Gilbert AS; Mann A; He D; Oxford JS; Burt D
    PLoS One; 2016; 11(12):e0163089. PubMed ID: 28005959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.
    Memoli MJ; Czajkowski L; Reed S; Athota R; Bristol T; Proudfoot K; Fargis S; Stein M; Dunfee RL; Shaw PA; Davey RT; Taubenberger JK
    Clin Infect Dis; 2015 Mar; 60(5):693-702. PubMed ID: 25416753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
    Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
    Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
    Ameghi A; Pilehvar-Soltanahmadi Y; Baradaran B; Barzegar A; Taghizadeh M; Zarghami N; Aghaiypour K
    Viral Immunol; 2016 May; 29(4):228-34. PubMed ID: 27058011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination-challenge studies with a Port Chalmers/73 (H3N2)-based swine influenza virus vaccine: Reflections on vaccine strain updates and on the vaccine potency test.
    De Vleeschauwer A; Qiu Y; Van Reeth K
    Vaccine; 2015 May; 33(20):2360-6. PubMed ID: 25804707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A plant-produced influenza subunit vaccine protects ferrets against virus challenge.
    Mett V; Musiychuk K; Bi H; Farrance CE; Horsey A; Ugulava N; Shoji Y; de la Rosa P; Palmer GA; Rabindran S; Streatfield SJ; Boyers A; Russell M; Mann A; Lambkin R; Oxford JS; Schild GC; Yusibov V
    Influenza Other Respir Viruses; 2008 Jan; 2(1):33-40. PubMed ID: 19453491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.